keyword
sdspage
biod
fens
biomark
icat
im
munoproteom
ic
aldi
seldi
h
e
n
cr
ea
n
g
th
r
ea
b
ot
er
ro
r
c
n
u
e
em
er
g
en
c
e
n
ew
n
f
ect
u
di
e
es
h
ri
v
e
n
jor
r
e
su
rg
en
c
e
n
b
om
e
ca
l
r
es
e
ar
ch
eff
ev
el
p
pr
ov
ed
en
ts
di
g
n
os
cs
n
va
cc
n
es
l
l
n
c
e
th
e
f
u
n
e
n
ta
l
u
n
de
r
st
di
n
g
host
immun
respons
infecti
agent
avail
multipl
mass
pe
ct
ro
et
r
p
power
research
approach
gener
multitud
potenti
new
protein
target
howev
translat
proteom
discoveri
u
seful
counterbioterror
product
requir
larg
collabor
research
effort
across
multipl
basic
scienc
clinic
disciplin
translat
proteom
research
paradigm
illustr
approach
use
influenza
viru
exampl
discuss
expert
rev
proteom
content
multidimension
separ
ms
appro
ac
pat
hogen
proteomi
cs
ld
ms
appl
e
biodefens
sel
ditofm
ppli
ed
biodefens
u
n
p
r
e
c
nf
l
ue
n
za
c
l
c
al
bi
de
f
e
n
se
paradi
gm
ys
tem
pr
ot
eom
ic
p
lot
stu
dy
pr
oteom
applic
clinic
sampl
flumist
vacci
n
ee
ex
per
opi
n
fi
veyear
v
iew
key
iss
ue
refer
affili
fo
r
r
e
pr
n
rd
e
r
pl
e
se
c
n
ac
r
e
pr
n
f
u
u
r
e
ru
g
c
r
k
e
e
n
g
ch
w
eg
l
er
g
r
n
st
e
n
expert
rev
proteom
potenti
largescal
use
biolog
weapon
exist
sinc
end
world
war
ii
anthrax
letter
attack
usa
usher
new
immedi
need
improv
countermeasur
bioterror
agent
purpos
review
research
de
cription
herein
term
bioter
rorism
use
defin
nation
insti
tute
ergi
infecti
ou
di
seas
niaid
strateg
plan
biodefen
e
research
use
microorgan
caus
human
di
ea
e
toxin
deriv
harm
peopl
elicit
widespread
fear
intimid
societi
polit
ideolog
goal
scientif
medic
perspect
form
terror
best
seen
variant
gener
problem
emerg
infecti
diseas
differ
increas
virul
spread
suscept
popul
deliber
act
man
rather
consequ
natur
evolut
key
effect
counter
bioterror
agent
lie
develop
new
rapid
diagnost
test
new
vaccin
es
immunotherapi
prevent
new
drug
biolog
treatment
illu
strate
larg
number
potenti
bioterror
agent
includ
niaid
categori
ac
prioriti
pathogen
list
substanti
invest
biomed
research
properti
pathogen
immun
respons
requir
usa
alon
niaid
biodefens
re
ear
ch
budget
biomed
research
exceed
us
billion
alloc
type
resourc
biomed
research
offer
potenti
develop
util
ize
novel
technolog
i
regard
emerg
technolog
offer
much
promis
encompass
term
proteom
biomed
research
area
increasingli
provid
new
solut
treatment
bioter
rorism
agent
goal
review
summar
methodolog
experiment
rational
success
proteom
approach
alreadi
accomplish
context
bioterror
issu
primar
ili
use
anthrax
bacter
ia
exampl
emerg
area
immunoproteom
also
address
despit
enorm
potenti
applic
proteom
clin
ical
issu
biodefens
infecti
di
ea
e
research
gener
ar
e
rel
publ
icat
area
relat
diseas
cancer
latter
section
review
address
issu
clude
discuss
appli
proteom
sampl
relat
influenza
viru
infect
vaccin
natur
natur
influenza
infect
potenti
use
bioterror
weapon
make
influenza
model
paradigm
system
biodefens
proteom
applic
monitor
proteom
differ
bacteri
viral
pathogenesi
allow
direct
comparison
strain
variabl
sever
fection
environmen
tal
infl
uenc
effect
genet
manipul
primarili
carri
pathogen
bacteria
use
gel
electrophoresi
usual
involv
strain
exhibit
divers
phenotyp
includ
antivir
drug
resist
alter
degre
infect
pathogen
differ
growth
condit
differenti
genotyp
low
mass
rang
protein
isplay
method
matr
ixassi
ted
laser
desorpt
ioniz
ldi
timeofflight
tof
mass
spectrometri
ms
surfaceenhanc
laser
desorptionioniz
atio
n
e
ld
fm
al
ncreasi
ngl
appl
i
microbi
ystem
compar
proteom
techniqu
isotopecod
affin
tag
icat
well
differ
multidimension
chromatographi
system
bein
g
util
frontend
step
prior
ms
recent
ms
platform
fourier
transform
ion
cyclotron
reson
fticr
ms
also
appli
micr
obial
system
practic
type
lysat
fraction
deriv
es
cherichia
coli
frequent
util
character
differ
ms
platform
thu
surpris
proteom
public
biodefens
pathogen
involv
differenti
character
multi
ple
bacteri
al
proteom
b
l
e
summari
nd
represen
tativ
list
iffer
niai
prioriti
pathogen
ali
zed
typ
e
multidimens
separ
compar
display
method
follow
ms
sequenc
differenti
express
protein
present
list
intend
exhaust
scope
reflect
recent
pr
ot
eom
ch
aracter
studi
indic
prioriti
pat
hogen
includ
b
l
e
one
common
approach
use
studi
list
b
l
e
involv
separ
step
differenti
express
protein
target
identifi
excis
elut
gel
digest
trypsin
amino
acid
sequenc
tryptic
p
eptid
determin
use
iffer
maldi
instrument
configur
electrospray
iontrap
mass
spectromet
type
h
ybrid
stru
men
tation
cont
rast
mor
e
sophist
affinitybas
technolog
icat
underrepres
b
l
e
like
increasingli
appli
microbi
system
overal
type
studi
list
b
l
e
illustr
rang
exampl
achiev
differ
frontend
separ
comparison
method
singl
met
hod
current
superior
within
current
framework
rapidli
evolv
area
proteom
technolog
choic
method
appli
larg
depend
budgetari
proteom
resourc
avail
individu
investig
given
institut
organ
b
l
e
prioriti
pa
thogen
becom
candid
organ
genom
sequenc
effort
illustr
effect
human
genom
linkag
wit
h
proteom
tryptic
datab
ase
search
engin
tha
facilit
direct
peptid
sequenc
ident
iti
bacteri
genom
databas
organ
character
differenti
protein
express
greatli
enhanc
success
effort
regard
multitud
genom
databas
resourc
microb
exist
continu
rapidli
evolv
bacteri
genom
ad
databas
includ
avail
institut
genom
research
md
usa
max
planck
institut
germani
ot
site
access
via
internet
whic
h
also
summar
separ
pub
licat
anoth
critic
evolv
resourc
searchabl
polyacrylamid
gel
electrophoresi
page
imag
databas
differ
pathogen
iffer
host
cell
type
typifi
includ
ident
migrat
posit
alreadi
character
protein
refer
gel
similar
l
ess
preva
lent
icat
refer
databa
se
iffer
organ
also
establish
type
databas
resour
ce
greatli
decrea
e
redun
danci
sequenc
everi
protein
gel
icat
analysi
lastli
compar
bacteri
proteom
studi
could
analyz
use
anoth
emer
ging
tech
nolog
differ
ial
ingel
fluoresc
electrophoresi
dige
involv
differenti
label
two
relat
protein
sampl
iffer
color
dye
separ
sampl
mixtur
label
third
refer
dye
follow
separ
mixtur
standard
gel
alreadi
report
analysi
e
coli
like
play
increas
role
hese
type
bacteri
proteom
character
studi
use
selditof
proteincaptur
chip
surfac
malditof
wit
h
direct
applic
sampl
spot
plate
simultan
analysi
popul
protein
present
complex
biolog
materi
yield
profil
uniqu
specif
sampl
contr
ast
gel
str
ategi
seldi
mal
di
ap
proach
rapid
highth
roughpu
capabl
autom
assay
develop
requir
order
magnitud
lower
amount
protein
sampl
effect
resolv
lowmass
protein
da
restrict
mass
rang
disadvantag
comprehens
proteom
analysi
requir
approach
much
better
accomplish
gel
fticrm
method
mass
v
alu
multi
ple
poten
tial
bi
omar
ker
iden
tifi
ed
seldi
approach
major
limit
ation
seldi
use
effici
direct
amino
acid
sequenc
determin
biomark
candid
necessit
u
se
oth
er
trategi
purpos
new
gen
erat
alditof
tof
nstr
umen
tation
emer
gi
ng
tha
faci
lit
ate
identif
preval
peptid
fragment
less
masstocharg
ratio
thu
increas
type
p
roteom
profil
strategi
appli
biodefens
p
athogen
exampl
appli
maldi
biodefens
p
athogen
charact
eriz
summar
follow
paragraph
exampl
seldi
applic
present
nex
section
multipl
msbase
studi
report
character
uniqu
sporul
veget
properti
ba
cillu
sp
p
particularl
bacillu
anthraci
b
anthraci
str
ain
ar
e
found
throughout
world
howev
wide
geograph
distribut
reflect
great
genet
diver
iti
except
docu
ment
var
iabl
e
nu
mber
tandem
r
epeat
sequenc
singl
n
ucleotid
poli
morph
ism
use
phylogenet
relationship
genet
differ
import
understand
pat
hogenesi
b
n
hr
aci
proteom
method
appli
identif
protein
differenti
express
variou
cultur
condit
cours
infect
forens
biodefens
perspect
proteom
profil
approach
may
abl
identifi
uniqu
protein
signatur
specif
relat
spore
cultur
condit
well
differ
viru
lenc
strain
b
anthrac
b
n
hr
aci
spore
coat
surround
hydrophob
balloonlik
glycoprotein
shell
term
exosporium
multipl
studi
describ
differ
pr
otein
compon
exosporium
specif
prot
ein
includ
collag
en
like
st
ructur
al
protein
term
bcla
ot
inter
gral
membran
glycoprotein
multipl
embed
solubl
protein
racemas
uperoxid
dismut
ase
comprehens
analysi
thu
far
differ
protein
endospor
b
anthrac
stern
identifi
multidimension
chromatographi
tandem
ms
sequenc
etho
ds
given
complex
growth
variabl
spore
proteom
mani
strain
b
anthraci
higher
throughput
aldi
profil
strategi
could
provid
broader
complementari
inform
base
develop
countermeasu
re
ag
ainst
iver
se
thrax
str
ain
exampl
malditof
ana
lysi
tryptic
fragment
small
acidsolubl
spore
protein
bacillu
spp
proven
diagnost
differ
within
speci
mal
dit
tudi
report
ed
iffer
enti
al
p
rofil
es
l
owmass
peptidesprotein
could
det
ermin
spore
protein
differ
b
anthraci
str
ain
wer
e
c
omp
are
two
recent
report
evalu
biliti
convent
malditof
approac
h
new
hybrid
iontrap
malditof
instrument
rapidli
sep
arat
identifi
mixtur
peptid
eriv
limit
tryptic
proteolysi
mix
spore
five
bacillu
spp
follow
onprob
digest
immobil
trypsin
cleavag
prod
uct
limit
set
ba
cterial
protein
molec
ular
mass
approxim
kda
obtain
within
min
bacteri
pep
tide
suitabl
isol
highenergi
fragmentaion
ali
si
gener
ate
wit
hin
min
equenc
peptid
allow
ra
pid
identif
abund
protein
present
bacteri
sourc
use
standard
databa
se
search
sp
eciessp
cific
ryptic
peptid
could
b
e
gener
bacillu
sp
p
stu
die
relat
studi
novel
quadrupol
iontrap
tofm
use
nalyz
peptid
sequenc
gener
proteoli
z
ed
spore
mi
xtur
es
report
use
method
onprob
solubil
situ
proteolyt
digest
small
acidsolubl
spore
protein
differ
speci
present
mixtur
could
identifi
less
min
hybrid
instrument
result
mass
resolv
power
maldi
mass
accuraci
part
p
er
million
use
iontrap
tof
tandem
configur
sequencespecif
inform
isol
proton
peptid
store
ion
trap
gain
via
ta
ndem
ms
experi
averag
mass
resolv
power
product
ion
analysi
cumul
malditof
stud
i
illu
strat
e
potentia
l
appli
mass
spectromet
pot
ential
field
applicat
ion
quickli
resolv
identifi
complex
mix
ture
micr
obe
refl
ectiv
g
iven
en
viron
genom
inform
becom
avail
differ
pathogen
bacteria
well
bacteria
present
normal
given
system
approach
could
critic
multipl
biodefens
applic
emerg
first
resp
der
scen
ario
sel
dit
ofm
technolog
h
recen
tli
develop
facilit
protein
profil
complex
biolog
mixtur
modif
malditof
technolog
use
proteinchip
array
coat
chemic
surfac
eg
ionic
hydrophob
metal
affin
captur
protein
molecul
complex
mixtur
retain
protein
subsequ
analyz
fm
wi
th
aid
f
e
l
di
f
tware
r
et
e
ntate
map
gener
depict
masstocharg
ratio
correspond
molecular
weight
process
expand
mani
hundr
samp
le
populationspecif
protein
express
profil
deduc
characterist
assay
group
result
fingerprint
pat
tern
uniqu
designat
ed
group
new
strain
coronaviru
cov
identifi
caus
sever
acut
respiratori
syndrom
sar
infect
individu
led
death
worldwid
five
recent
studi
appli
proteom
profil
method
analyz
serum
plasma
cohort
collect
subset
sar
infect
patient
effort
identifi
earli
detect
prognost
biomark
three
studi
selditof
protein
chip
profil
use
distinct
sera
p
lasma
cohort
largest
report
studi
serum
sampl
separ
acut
sar
n
day
onset
fever
nonsar
n
cohort
larg
nonsar
cohort
includ
sampl
indic
fever
influenza
n
pneumonia
n
lung
cancer
n
healthi
control
n
sampl
incub
weak
cation
proteinchip
ciphergen
biosystem
follow
selditof
spect
ra
gener
peak
ident
etermin
panel
four
biomark
peak
could
detect
sensit
acut
sar
specif
nonsar
sampl
four
peak
could
also
use
distinguish
acut
sar
fever
influenza
cohort
specif
conclu
ded
approach
could
form
basi
serum
proteom
profil
assay
ea
rli
detect
sar
infect
separ
seldi
studi
profil
longitudin
sera
sampl
collect
sar
patient
compar
wit
h
sera
control
patient
without
sar
total
distinct
protein
peak
identifi
differenti
diagn
ostic
sar
one
ser
um
amyloid
saa
subsequ
sa
concentr
ation
deter
minat
lon
gitudin
al
serum
sampl
found
good
cor
relat
saa
concentr
wit
h
extent
pneumonia
small
ubset
sever
sar
case
like
identit
i
function
p
roperti
differ
serum
protein
marker
identifi
seldi
peak
repres
acutephas
reactant
consist
crit
icism
prot
eomic
profil
serum
approach
peak
reflect
innat
immun
respons
pathogenderiv
protein
suffici
studi
definit
determin
answer
question
nd
possibl
peak
repres
possibl
without
fraction
remov
major
serum
plasma
protein
prior
seldi
analysi
like
differenti
marker
reflect
acutephas
respons
howev
preclud
use
diag
nostic
andor
distinct
p
articular
ty
pe
viral
nfecti
exampl
n
ge
l
studi
f
plasma
sampl
four
sar
patient
major
differenti
express
protein
identifi
acutephas
protein
clude
novel
marker
peroxiredoxini
secret
tcel
ls
author
hypothes
type
tcelld
eriv
marker
could
reflect
innat
immun
signal
cascad
result
sarscov
infect
much
work
remain
done
identif
lowmass
serum
biomark
applic
complex
bodi
fluidderiv
mixtur
es
hybrid
iontr
ap
ldi
strumen
ts
descr
ibe
spore
protein
mixtur
could
facilit
effort
follow
differ
protein
display
identif
studi
mention
previous
method
could
funnel
toward
directli
adapt
develop
improv
vaccin
identifi
antigen
compon
differ
pathogen
immunoproteom
given
pathogen
consist
identifi
antigen
present
infect
host
recognit
everi
potenti
epitop
deriv
pathogen
genom
appear
requir
effect
immun
respons
occur
subset
antigen
epitop
provid
necessari
protectionneutr
electrophoresi
blot
wholecel
lysat
membraneenrich
fraction
provid
display
method
identifi
clinic
relev
subset
antigen
follow
incub
blot
pathogenexpos
sera
sampl
vivo
antigen
particular
pathogen
thu
identifi
follow
ms
sequenc
highresolut
electrophoresi
unambigu
identif
prerequisit
reliabl
result
statist
analysi
result
antigen
candid
diagnost
assay
vaccin
develop
andor
target
therapi
specif
prioriti
pathogen
list
differ
immunoproteom
studi
report
franci
ell
tularensi
th
rax
higel
la
mycobact
ium
tuberc
ul
osi
exampl
attenu
live
vaccin
strain
f
tularensi
use
gener
wholecel
lysat
integr
membran
protein
fraction
basic
protein
fraction
separ
gel
transfer
nitrocellulos
sera
coll
ect
patient
suffer
tularemia
use
probe
immunoblot
compar
control
sera
healthi
donor
sera
patient
lyme
diseas
approach
potenti
antigen
spot
identifi
maller
subset
select
ms
sequenc
analysi
sera
patient
tularemia
found
predomin
antigen
speci
differ
variant
chaperonin
isol
integr
membran
wholecel
lysat
anoth
exampl
recent
describ
th
rax
b
anthraci
use
sera
infect
anim
antibodi
sourc
studi
uniqu
describ
predict
comput
screen
anthrax
genom
identifi
vaccin
candid
compar
result
function
immunoproteom
assay
six
eight
protein
vivo
screen
previous
identifi
antigen
five
eight
protein
predict
comput
screen
studi
illustr
ate
combin
ing
resourc
avail
particular
antigen
eg
genom
proteom
immunolog
vivo
infect
model
gener
n
ovel
vaccin
candid
prioriti
pathogen
develop
assay
system
provid
capabl
perform
type
comprehens
experiment
approach
emphas
anoth
immunoproteom
approach
focus
character
pa
thogenderiv
peptid
bound
major
histocompat
complex
mhc
antigenpres
cell
elicit
effector
tcell
respons
pathogen
follow
immunoaffin
purif
dissoci
bound
p
ep
tide
mhc
complex
peptid
sequenc
tandem
ms
identifi
peptid
thu
repres
pot
ential
vaccin
candid
pathogen
ap
proach
recent
ly
comprehens
review
potenti
highli
effect
coupl
comprehens
analysi
strategi
describ
preced
paragraph
author
proteom
effort
biodefens
research
within
next
year
center
develop
diagnost
assay
improv
fluenza
vaccin
e
str
ategi
comprehens
character
immun
respons
influenza
viru
infect
author
believ
human
influenza
viru
ideal
model
comprehens
proteom
character
viru
import
biodefenseinfecti
diseas
threat
influenza
viru
paradigm
base
mu
lti
ple
con
si
derati
bioen
gineer
infl
uenza
vir
us
g
enerat
e
v
iral
strain
never
previous
seen
hu
man
popul
remain
l
oom
bioterror
threat
addit
influenza
strain
could
engin
drug
resist
current
antiinfluenza
drug
introduct
strain
could
devast
consequ
essenti
creat
super
carrier
infect
th
woul
pread
rap
idl
th
rough
immunena
ive
human
popul
realist
scena
rio
present
laboratori
possess
requisit
tool
g
ener
recombin
viru
tock
howev
like
chang
within
next
year
guarante
made
technolog
end
possess
ion
bioter
rorist
contain
natur
influenza
infect
still
remain
daunt
challeng
influenza
lead
caus
catastroph
disabl
greatli
affect
qualiti
life
elderli
person
usa
alon
estim
us
billion
spent
annual
due
imp
act
influenza
cost
rise
popul
senior
citizen
rapidli
expa
nd
influenza
morbid
mortal
realiz
primarili
older
adult
cau
sed
immu
ne
respons
influenza
viru
specif
elev
level
cytokin
associ
influenza
symptom
includ
fever
headach
host
immun
respons
viral
pathogen
quit
variabl
pathogen
current
influenza
vaccin
cost
effect
far
perfect
vaccin
elderli
peopl
still
acquir
influenza
infect
antibodi
respons
vaccin
declin
age
mechan
respons
declin
remain
elus
b
etter
vaccin
well
earli
diagnosi
novel
treatment
target
harm
expert
rev
proteom
immun
resp
ons
bring
hu
ge
advan
ce
diseas
prev
ention
nd
con
tainment
benefici
biodefens
issu
mana
ging
natura
l
diseas
outbreak
proteom
strategi
thu
key
make
need
realiti
tain
goal
readili
feasibl
whole
repertoir
reagent
model
vail
abl
influ
en
za
research
includ
welldefin
viral
stock
prepar
methodolog
cell
line
anim
infect
model
clinic
million
individu
vaccin
influenza
million
infect
natur
year
challeng
strain
defin
antibodi
detect
assay
clinic
use
antivir
agent
also
avail
cumul
obtain
statist
signific
number
research
sa
mple
relat
influenza
fect
io
ns
r
vacci
nati
ns
w
il
l
str
aig
htf
rw
ard
f
heir
collect
incorpor
studi
protocol
exampl
author
preliminari
experi
indic
tha
elderli
adult
lower
tcell
respons
influenza
vaccin
young
adu
lt
reduc
respons
proport
reduc
antibodi
respons
mechan
ageassoci
declin
respons
precis
caus
senesc
lead
reduc
antibodi
respon
e
el
derli
peopl
ar
ea
fut
ure
research
use
differ
prot
eomic
analys
appli
serum
immun
cell
isol
author
hope
identifi
surrog
marker
associ
either
antibodi
andor
tcell
respons
character
surrog
marker
investig
role
immun
e
senescen
ce
dditi
onal
ly
n
event
bi
oterrorist
tack
nat
ural
outbrea
k
infecti
diseas
sar
earli
diagnosi
pivot
treatment
conta
inment
outbreak
author
believ
character
identifi
host
immun
respons
infect
use
earli
diagnosi
well
new
trea
tment
strategi
target
harm
aspect
host
immun
respons
influenza
ideal
system
appli
current
emerg
proteom
technolog
accomplish
goal
two
exampl
recent
pilot
studi
p
roteom
profil
strategi
appli
vaccin
subject
present
next
section
illustr
effect
approach
could
clinic
biodefens
studi
glenn
cen
ter
va
usa
six
healthi
young
volunt
year
age
recruit
receiv
ed
live
viru
flumist
vaccin
e
intran
alli
serum
nasal
swab
obtain
subject
immedi
day
day
post
vaccin
serum
dramat
differ
enc
seldi
profil
observ
particularli
day
compar
day
three
chip
surfac
distinct
protein
significantli
p
overor
underexpr
es
sed
day
ser
six
flu
mistvaccin
subject
figur
kda
gel
view
comparison
day
flumist
recipi
present
three
chip
surfac
peak
reflect
transient
increas
decreas
day
rebound
near
day
valu
day
besid
highlight
chang
day
figur
also
illustr
use
multipl
chip
surfac
increas
avail
number
potenti
biomark
could
target
identif
sequenc
nasal
swab
sampl
obtain
time
sera
sampl
urprisingli
ly
sampl
fr
om
day
postflumist
ad
ministr
ind
icat
differen
ce
protein
profil
rel
day
baselin
profil
repres
p
rofil
e
day
v
ersu
day
fl
umist
recipi
shown
f
g
u
r
e
note
larg
differ
intens
scale
two
sampl
signific
upregul
protein
kda
rang
lower
mass
region
within
box
kda
four
six
flu
mist
recipi
similar
respons
day
protein
return
baselin
day
data
shown
sodium
dodecyl
sulfat
egel
use
separ
swab
fluid
day
flumist
recipi
three
band
approxim
kda
excis
gel
protein
elut
trypsin
nd
appli
lcq
decaxp
esi
mass
sp
ectromet
thermofinnigan
kda
band
three
nonredund
peptid
match
human
palat
lung
nasal
epitheli
clone
plunc
found
plunc
newli
discov
gene
famili
similar
human
bactericidalpermeabilityincreas
protein
mammalian
lipopolysaccharidebind
lipid
ransport
p
rotein
kda
protein
sequenc
identif
hypothet
identifi
two
put
membran
protein
unknown
function
summari
intent
present
pilot
seldi
studi
flumist
vaccine
illustr
clearli
distinct
detect
biolog
differ
present
serum
nasal
swab
protein
extract
whatev
proteom
platform
avail
particular
investig
incorpor
longitudin
collect
bodi
fluid
du
ring
vaccin
treatment
trial
pathogen
consid
fluid
repres
larg
uncharacter
reservoir
potenti
biomark
vaccin
efficaci
treatment
respons
diseas
p
rogress
th
er
appl
ica
tio
ns
context
util
proteom
relat
resourc
biodefens
applic
reason
great
optim
well
reason
great
concern
excel
p
rogress
appli
develop
innov
ad
vanc
proteom
resourc
applica
tion
bacteri
pathog
en
part
icul
arl
ant
hrax
clear
converg
enc
pr
oteom
genom
immunolog
infor
mation
evid
h
old
great
promis
design
improv
vaccin
identificat
ion
new
treatment
target
mechanist
function
inform
gain
studi
posit
impact
mani
area
hu
man
health
research
eventu
collater
benefit
proteom
methodolog
develop
biodefens
applic
could
enorm
ap
pli
less
pathogen
bacteri
infect
human
anim
plant
diseas
differ
environment
system
statement
base
current
proteom
technolog
sinc
one
rapidli
evolv
area
biomed
research
reason
expect
even
bett
er
method
instrument
quickli
emerg
biodefens
applic
cont
rast
progress
bacteri
pa
thogen
ap
plicat
proteom
viral
pat
hogen
embarrassingli
spars
bodi
literatur
field
even
studi
relat
hiv
includ
nd
great
caus
concern
context
bioterror
threat
public
health
gener
almost
mani
proteomicrel
report
evalu
clinic
specimen
sar
patient
report
hi
v
fluenza
al
l
virus
prioriti
pathogen
list
combin
even
inclus
cell
lineor
anim
modelrel
proteom
stud
i
signific
ly
alter
statement
clearli
improv
strategi
appli
proteom
viral
infect
need
henc
discuss
influenza
paradigm
system
includ
attempt
initi
encourag
type
studi
author
opinion
situat
reflect
l
arg
eli
reactionar
research
viewpoint
whatev
infecti
diseas
bioterror
pathog
en
current
ly
news
one
h
ben
efici
argument
increas
understand
anthrax
infect
develop
countermeasur
need
hope
type
studi
referenc
herein
illustrat
e
progress
great
pot
ential
benefit
deriv
proteom
analys
anthrax
hand
proteom
report
sar
far
result
far
less
mortal
typ
ical
flu
season
usa
viral
pathogen
hat
urgent
biodefens
threat
need
wait
avian
flu
final
ly
adapt
viru
lent
human
train
wor
se
wait
bioengin
strain
releas
initi
intens
studi
ar
gument
goin
g
critic
continu
research
sar
encourag
increas
applic
proteom
preva
lent
andor
morbid
virus
comprehens
approach
ie
proteom
genom
immunolog
appli
anthrax
research
readili
adapt
studi
influenza
viru
h
iv
mani
virus
prioriti
pathogen
list
context
biodefens
applic
next
year
bring
wea
lth
emerg
rapidli
expand
resourc
fa
cilit
increas
proteom
app
licat
bacteri
viral
yst
em
mul
tid
imen
sion
al
sep
arat
method
coupl
ms
analysi
tryptic
peptid
biodefenserel
bacteri
proteom
list
b
l
e
highlight
util
prote
omic
approach
one
like
continu
find
increas
use
differ
frontend
separ
technolog
emerg
obvious
microbialvir
genom
avail
differ
speci
easier
perform
funct
ional
proteom
studi
inc
reas
gel
refer
site
also
greatli
fa
cilit
effor
ts
similar
ly
icat
r
efer
ite
equa
lli
critic
path
clear
applic
dige
host
futur
icat
approach
readili
accomplish
access
fticrm
instrument
inc
reas
coupl
appropri
genom
databas
unpreced
opportun
fulli
character
p
roteom
individu
bacter
ia
l
pathogen
well
host
resp
ons
v
ir
al
bacteri
infect
clinica
l
pplic
ation
p
rote
omic
typ
i
seldi
maldi
analysi
b
lood
fluid
lesson
lreadi
learn
app
lie
se
technolog
evelop
cancer
diagnost
includ
cent
stud
eva
lu
ate
vira
l
patiti
condit
liver
canc
er
thousand
proteom
serum
analys
perform
cancer
diagnost
cumu
la
tive
exp
erien
ce
ha
high
lig
hte
eve
ral
area
need
improv
type
profil
studi
includ
establish
uniform
sampl
acquisit
process
storag
protocol
resolv
ms
instrument
peak
sensitivityresolut
issu
well
improv
data
analysi
tool
fact
issu
readili
addressa
ble
act
ive
pursu
cross
multipl
clinic
academ
biotechnolog
biopharmaceut
level
highli
encourag
issu
specif
cancerr
late
studi
equal
applic
biodefens
studi
order
largescal
proteom
profil
studi
accomplish
initi
readili
avail
clinic
specimen
associ
biodefens
pathogen
influenza
addit
consider
mention
whenev
cli
nical
tr
ial
bei
ng
desi
gned
pr
ospectiv
e
sampl
e
co
l
lectio
n
includ
studi
design
particularli
blood
draw
alreadi
like
compon
depend
studi
avai
labl
fl
uid
al
col
lect
eg
urin
e
n
al
fluid
saliva
anoth
approach
would
use
archiv
sampl
previou
clinic
trial
either
way
necessari
accomplish
type
studi
creat
integr
collabor
framework
protein
chemist
mass
spectroscopist
sampl
acquisit
biorepositori
staff
biostatistician
epidemiologist
clinicianspathologist
patient
cooper
consent
defici
individu
categori
compromis
outcom
entir
project
assay
level
need
continu
develop
highthroughput
reproduc
protein
fraction
procedur
identifi
potenti
lowconcentr
protein
biomark
key
achiev
develop
interand
intrainstitut
translat
research
group
bring
togeth
necessari
resourc
capit
immens
promis
proteom
technolog
applic
biodefens
relat
research
polyacryla
mide
gel
electrophoresi
pa
ge
w
ith
mass
spectrometri
ms
identifi
ca
tion
still
access
approach
c
hara
c
terizin
g
th
e
p
roteo
es
bac
terial
pa
tho
gen
pro
ved
ium
dec
yl
su
lfate
pag
e
eth
log
i
su
c
h
differenti
gel
electrophoresi
refin
extend
inform
gather
approach
increas
applic
isotopecod
affin
tag
method
fourier
transform
ion
cyclotron
reson
ms
character
bacteri
proteom
expand
dynam
rang
bacteri
proteom
es
greatli
facilit
discoveri
new
therapeut
vaccin
target
immunoproteom
applic
repres
potential
power
converg
clinic
proteom
nd
genom
resourc
develop
improv
vaccin
differ
pathogen
proteomi
c
profil
serumplasma
va
ccinat
pathogenexpos
individu
use
matrixassist
la
ser
desorptionion
timeofflight
ms
surfaceenhanc
laser
desorptionion
timeofflight
ms
larg
untap
biomark
discoveri
diagnost
approach
aggress
pursu
particularli
virus
colla
bor
multiinstitut
multi
disciplin
multipl
technolog
effort
ne
ede
effect
clinic
studi
design
sampl
collect
sampl
analysi
diagnost
biodefens
pathogen
assay
develop
